Results 221 to 230 of about 1,170,184 (286)
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension phase).
Fabrizio De Benedetti +19 more
wiley +1 more source
Collective action for responsible global health data sharing and use. [PDF]
Mayor A +3 more
europepmc +1 more source
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg +20 more
wiley +1 more source
Climate and health governance: Opportunities and challenges addressing extreme heat in the United States. [PDF]
Ring NL, Daley DM, Brunsell NA.
europepmc +1 more source
Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Pascal Richette +13 more
wiley +1 more source
Celebrating the 30th Anniversary Year of the Founding of <i>The Permanente Journal</i>. [PDF]
Holt GR.
europepmc +1 more source
Objective Pulmonary fibrosis (PF) is a severe extra‐articular manifestation of rheumatoid arthritis (RA). This study aimed to externally validate a genetic risk score (GRS) and a combined risk score (CRS) for predicting the risk of RA‐associated PF in an independent cohort of patients with early RA.
Mikael Brink +3 more
wiley +1 more source
Governance and Update Process for Lifestyle Medicine Core Competencies and Definitions. [PDF]
Rea BL +8 more
europepmc +1 more source
Objective Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti–collagen II (Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick +6 more
wiley +1 more source
Clearing the air: a systematic review on leadership challenges with sustainable inhaler prescribing. [PDF]
Kajitani S +6 more
europepmc +1 more source

